The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

EUS-guided Versus Percutaneous Ultrasound-guided Biopsy for Parenchymal Liver Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06047327
Recruitment Status : Not yet recruiting
First Posted : September 21, 2023
Last Update Posted : September 21, 2023
Sponsor:
Information provided by (Responsible Party):
Institute of Liver and Biliary Sciences, India

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Liver biopsy may be indicated in various clinical scenarios to help diagnose and manage liver diseases. Endoscopic ultrasound (EUS) liver biopsy and percutaneous USG guided liver biopsy are two methods used to obtain liver tissue samples. EUS involves using an endoscope with an ultrasound probe to guide a needle through the stomach wall and into the liver, while percutaneous ultrasound guided biopsy involves inserting a needle directly through the skin and into the liver using ultrasound guidance.

A specimen measuring 15 mm or more and containing 6 to 8 CPTs is generally considered adequate for the histologic diagnosis of diffuse liver disease. However, stricter requirements of specimen length of 20 mm or longer with 11 or more CPTs for reliable grading and staging of chronic viral hepatitis have been recommended. With this study we aim to study in a head-to-head comparison between EUS-guided and percutaneous (PC) liver biopsies, with regards to tissue acquisition adequacy.


Condition or disease Intervention/treatment Phase
Liver Cirrhosis Diagnostic Test: EUS guided liver biopsy Diagnostic Test: Percutaneous Liver Biopsy Not Applicable

Detailed Description:

Aim and Objective - EUS-LB with a 19G Franseen needle is non-inferior to PC-LB with a 18G BioPince Needle, with regards to total specimen length and diagnostic adequacy.

Hypothesis - i. EUS-LB with a 19G FNB needle is non-inferior to PC-LB with a 18G full core biopsy needle, with regards to total specimen length and diagnostic adequacy.

ii. There would be lesser procedure related pain and higher patient satisfaction with EUS-LB compared to PC-LB.

Study population:

  1. Patients > 18 years of age.
  2. Eligibility for deep sedation with propofol.
  3. Undergoing liver biopsy for diagnosis/evaluation/staging.

Study design: All consecutive in-patients and out-patients requiring liver biopsy for evaluation of diffuse parenchymal liver disease will be evaluated for inclusion.

Study period: 1 year

  • Sample size with justification: The percentage success rate of procurement of adequate liver biopsies (defined by specimen length ≥ 15 mm and ≥ 8 CPTs) was assumed to be 90% with PC-LB based on two recent retrospective studies comparing PC-LB with EUS-LB. These studies used the bigger 16G Biopince needles. (Literature: Bhogal N. Endosc Int Open 2020, 99%; Facciorusso A. Cancers 2021, 100%). With similar criteria for adequacy, the success rates with EUS-LB were assumed to be 85% for non-inferiority comparison, based on recent studies of EUS-LB using 19G Franseen needles. (Literature: Hashimoto R. Dig Dis Sci 2020, 100%; Aggarwal SN. GIE 2021, 97.2%; Nallapeta N. Hepatology 2021, 55.6%)
  • With alpha-value of 10%, power of 80%, and non-inferiority margin of 10%, we need to enroll 44 patients in each of PC-LB and EUS-LB arms, for a total sample size of 88 patients. We plan to enroll 90 patients in this trial to account for technical inadequacies.
  • Intervention: Patient after screening for all exclusion criteria will be randomized into either EUS guided liver biopsy or USG guided percutaneous biopsy
  • Monitoring and assessment: All patients would undergo vital and baseline parameter screening before randomization. Based on randomization they will undergo the liver biopsy procedure. Post procedure all the patients will be closely observed in the recovery area for at least 4 hours after the procedure, VAS for pain will be noted & 4-point patient satisfaction scale will be provided to them. They will be followed up after 72 hours by a phone call or in their rooms if updated to check for any adverse effects.
  • Pain will be assessed with a visual analogue scale (VAS) score (minimum score = 0, maximum score = 10).
  • Patient satisfaction will be evaluated by using a four-point scale ('Very satisfied', 'Satisfied', 'Less satisfied' and 'Not satisfied at all').
  • Statistical Analysis: Descriptive data following a normal distribution will be reported as means (+ standard deviation [SD]), whereas nonparametric data will be reported as median (range). Comparisons between the two needles will be performed with a t test, Wilcoxon rank sum test, or chi-square test as appropriate.
  • A Mantel-Haenszel test of trend will be performed to determine whether a linear association existed between EUS-LB sampling and VCTE and CAP results.
  • Adverse effects:

AEs will be defined as any deviation from the anticipated intra-procedure and post-procedural course.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: EUS-guided Versus Percutaneous Ultrasound-guided Biopsy for Parenchymal Liver Disease: A Randomized Controlled, Non-inferiority Trial
Estimated Study Start Date : September 15, 2023
Estimated Primary Completion Date : August 31, 2024
Estimated Study Completion Date : August 31, 2024

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: EUS Guided Liver Biopsy
Procedure will be done by 19G Franseen needle in EUS guided liver biopsy.
 Diagnostic Test: EUS guided liver biopsy
Procedure will be performed by 19G Franseen needle.
Active Comparator: Percutaneous Liver Biopsy
Procedure will be done by 18G BioPince Needle in percutaneous liver biopsy.
 Diagnostic Test: Percutaneous Liver Biopsy
procedure will be done by 18G BioPince Needle


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Specimen adequacy defined by total specimen length (TSL) ≥ 15 mm and ≥ 8 complete portal triads (CPTs) [ Time Frame: Day 0 ]

Secondary Outcome Measures :
  1. Post-procedure pain measured on Visual Analogue Scale from (Minimum: 0, Max:10) [ Time Frame: 4 hours ]
  2. Pre-fix longest intact specimen length. [ Time Frame: 3 days ]
  3. Pre-fix aggregate specimen length. [ Time Frame: 3 days ]
  4. Total specimen complete portal tracts (CPTs). [ Time Frame: 3 days ]
  5. Proportion of specimens >20mm in aggregate length. [ Time Frame: 3 days ]
  6. Proportion of specimens with >11 CPTs. [ Time Frame: 3 days ]
  7. Total number of fragments. [ Time Frame: Day 0 ]
  8. Total Number of fragments >9mm. [ Time Frame: 3 days ]
  9. Proportion of specimens with a conclusive etiological diagnosis [ Time Frame: 3 days ]
  10. Proportion of specimens with a conclusive pathological diagnosis [ Time Frame: 3 days ]
  11. Adverse events after the procedure [ Time Frame: 72 hours ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients > 18 years of age.
  2. Eligibility for deep sedation with propofol.
  3. Undergoing liver biopsy for diagnosis/evaluation/staging.

Exclusion Criteria:

  1. Coagulopathy, defined by platelet count < 70,000/mL and/or INR > 1.7.
  2. Inability to discontinue anticoagulation or antiplatelet agents for 5 days prior to the procedure.
  3. Presence of unrelieved biliary obstruction.
  4. Presence of ascites.
  5. Suspected or known hepatic malignancy.
  6. Hypertensive patients with uncontrolled blood pressure. (SBP >150 and/or DBP>100mmHg)
  7. Medically unfit for sedation.
  8. Inability to provide informed consent.
  9. Cannot understand Hindi or English should be excluded since they will not be able to reply objectively to questionnaire.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06047327


Contacts
Layout table for location contacts
Contact: Dr Ishank Johri, MD 01146300000 ishankjohri@gmail.com

Locations
Layout table for location information
India
Institiute of liver and biliary sciences
New Delhi, India, 110070
Contact: Dr Ishank Johri, MD    01146300000    ishankjohri@gmail.com   
Sponsors and Collaborators
Institute of Liver and Biliary Sciences, India
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Institute of Liver and Biliary Sciences, India
ClinicalTrials.gov Identifier: NCT06047327    
Other Study ID Numbers: ILBS-EUS-01
First Posted: September 21, 2023    Key Record Dates
Last Update Posted: September 21, 2023
Last Verified: September 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Liver Cirrhosis
Digestive System Diseases
Fibrosis
 Pathologic Processes
Liver Extracts
Hematinics